Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azilsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.67 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilsartan SCHEMBL29687472 | 1.00 | AGTR2 (0.72) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL15552225 | 0.99 | AGTR2 (0.71) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL969381 | 0.99 | AGTR2 (0.71) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL21083535 | 0.94 | AGTR2 (0.65) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL29726876 | 0.94 | AGTR2 (0.65) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL683647 | 0.93 | AGTR2 (0.64) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL6111486 | 0.93 | AGTR2 (0.63) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL19158920 | 0.92 | AGTR2 (0.63) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL3770221 | 0.92 | AGTR2 (0.70) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL969380 | 0.92 | AGTR2 (0.70) | AGTR2ABCB11EGFRERBB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2423 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036956-A | Monoclonal antibody, nucleic acid molecule, detection kit and application of non-biphenyl tetrazolium sartan drugs | 中南大学湘雅三医院 | 2026-05-15 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260083726-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS, CHEMOTHERAPEUTIC AGENTS, AND ANTI-FIBROTIC AGENTS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| EP-4694856-A1 | CALENDAR MEDICATION BLISTER PACK, METHOD OF USING THEREOF AND ELECTRONIC SYSTEM OF MANAGEMENT OF INTERACTION WITH CALENDAR MEDICATION BLISTER PACK | Mili Healthcare Trade Fzco (AE) | 2026-02-18 | — | — | EP | claimed |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-12-25 | — | — | US | claimed |
| EP-2916851-B1 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | VIFOR INT LTD (CH) | 2025-12-17 | — | — | EP | claimed |
| US-20250367170-A1 | TOPICAL ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR TREATING EYE CONDITIONS | CLEVELAND CLINIC FOUND (US) | 2025-12-04 | — | — | US | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250360106-A1 | PREVENTING IMMUNOTHERAPY-INDUCED EDEMA USING ANGIOTENSIN RECEPTOR BLOCKERS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-11-27 | — | — | US | claimed |
| US-6469037-B2 | Prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-22 | — | — | US | claimed |
| EP-0612523-B1 | Vascular hypertrophy suppressor | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | claimed |
| US-20020045652-A1 | Prophylactic or therapeutic drug for renal diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-04-18 | — | — | US | claimed |
| EP-0622077-B1 | Angiotensin II antagonists as a prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-07-05 | — | — | EP | claimed |
| EP-0612524-B1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-26 | — | — | EP | claimed |
| US-5736561-A | ANGIOTENSIN II ANTAGONIST FOR PROPHYLAXIS OR TREATMENT AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, FOR VASCULAR RESTENOSIS AFTER BYPASS SURGERY AND FOR PROGRESSIVE ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-07 | — | — | US | claimed |
| US-5605919-A | PREVENTION OF CELL INJURY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-25 | — | — | US | claimed |
| EP-0622077-A1 | Angiotensin II antagonists as a prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-02 | — | — | EP | claimed |
| EP-0612523-A1 | Vascular hypertrophy suppressor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0612524-A1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |